The first major scientific article on the antimicrobial peptide SAAP-148 appeared today in Science Translational Medicine
In this paper, scientists from LUMC, AMC and the Association of Dutch Burn Centers tested SAAP-148 in bacterial cultures in the lab and models of injured skin. The results were positive: all bacteria were eliminated, including bacteria that were resistant to antibiotics and even bacteria that had formed a protective layer around them called biofilms.
SAAP-148 is the lead product of Madam Therapeutics, and is anticipated to enter the first clinical trials in humans in 2018.
Full PR available here